BACKGROUND: Arthrogryposis, defined as congenital joint contractures in 2 or more body areas, is a clinical sign rather than a specific disease diagnosis. To date, more than 400 different disorders have been described that present with arthrogryposis, and variants of more than 220 genes have been associated with these disorders; however, the underlying molecular etiology remains unknown in the considerable majority of these cases. METHODS: We performed whole exome sequencing (WES) of 52 patients with clinical presentation of arthrogryposis from 48 different families. RESULTS: Affected individuals from 17 families (35.4%) had variants in known arthrogryposis-associated genes, including homozygous variants of cholinergic γ nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects). Deleterious variants in candidate arthrogryposis-causing genes (fibrillin 3 [FBN3], myosin IXA [MYO9A], and pleckstrin and Sec7 domain containing 3 [PSD3]) were identified in 3 families (6.2%). Moreover, in 8 families with a homozygous mutation in an arthrogryposis-associated gene, we identified a second locus with either a homozygous or compound heterozygous variant in a candidate gene (myosin binding protein C, fast type [MYBPC2] and vacuolar protein sorting 8 [VPS8], 2 families, 4.2%) or in another disease-associated genes (6 families, 12.5%), indicating a potential mutational burden contributing to disease expression. CONCLUSION: In 58.3% of families, the arthrogryposis manifestation could be explained by a molecular diagnosis; however, the molecular etiology in subjects from 20 families remained unsolved by WES. Only 5 of these 20 unrelated subjects had a clinical presentation consistent with amyoplasia; a phenotype not thought to be of genetic origin. Our results indicate that increased use of genome-wide technologies will provide opportunities to better understand genetic models for diseases and molecular mechanisms of genetically heterogeneous disorders, such as arthrogryposis. FUNDING: This work was supported in part by US National Human Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) grant U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics, and US National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS058529 to J.R. Lupski.
BACKGROUND:Arthrogryposis, defined as congenital joint contractures in 2 or more body areas, is a clinical sign rather than a specific disease diagnosis. To date, more than 400 different disorders have been described that present with arthrogryposis, and variants of more than 220 genes have been associated with these disorders; however, the underlying molecular etiology remains unknown in the considerable majority of these cases. METHODS: We performed whole exome sequencing (WES) of 52 patients with clinical presentation of arthrogryposis from 48 different families. RESULTS: Affected individuals from 17 families (35.4%) had variants in known arthrogryposis-associated genes, including homozygous variants of cholinergic γ nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects). Deleterious variants in candidate arthrogryposis-causing genes (fibrillin 3 [FBN3], myosin IXA [MYO9A], and pleckstrin and Sec7 domain containing 3 [PSD3]) were identified in 3 families (6.2%). Moreover, in 8 families with a homozygous mutation in an arthrogryposis-associated gene, we identified a second locus with either a homozygous or compound heterozygous variant in a candidate gene (myosin binding protein C, fast type [MYBPC2] and vacuolar protein sorting 8 [VPS8], 2 families, 4.2%) or in another disease-associated genes (6 families, 12.5%), indicating a potential mutational burden contributing to disease expression. CONCLUSION: In 58.3% of families, the arthrogryposis manifestation could be explained by a molecular diagnosis; however, the molecular etiology in subjects from 20 families remained unsolved by WES. Only 5 of these 20 unrelated subjects had a clinical presentation consistent with amyoplasia; a phenotype not thought to be of genetic origin. Our results indicate that increased use of genome-wide technologies will provide opportunities to better understand genetic models for diseases and molecular mechanisms of genetically heterogeneous disorders, such as arthrogryposis. FUNDING: This work was supported in part by US National Human Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) grant U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics, and US National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS058529 to J.R. Lupski.
Authors: Niklas Krumm; Peter H Sudmant; Arthur Ko; Brian J O'Roak; Maika Malig; Bradley P Coe; Aaron R Quinlan; Deborah A Nickerson; Evan E Eichler Journal: Genome Res Date: 2012-05-14 Impact factor: 9.043
Authors: J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman Journal: Eur J Pediatr Date: 2007-11-23 Impact factor: 3.183
Authors: Alistair T Pagnamenta; Malcolm F Howard; Eva Wisniewski; Niko Popitsch; Samantha J L Knight; David A Keays; Gerardine Quaghebeur; Helen Cox; Phillip Cox; Tamas Balla; Jenny C Taylor; Usha Kini Journal: Hum Mol Genet Date: 2015-04-08 Impact factor: 6.150
Authors: M Brigita Tan-Sindhunata; Inge B Mathijssen; Margriet Smit; Frank Baas; Johanna I de Vries; J Patrick van der Voorn; Irma Kluijt; Marleen A Hagen; Eveline W Blom; Erik Sistermans; Hanne Meijers-Heijboer; Quinten Waisfisz; Marjan M Weiss; Alexander J Groffen Journal: Eur J Hum Genet Date: 2014-12-24 Impact factor: 4.246
Authors: Davut Pehlivan; Yavuz Bayram; Nilay Gunes; Zeynep Coban Akdemir; Anju Shukla; Tatjana Bierhals; Burcu Tabakci; Yavuz Sahin; Alper Gezdirici; Jawid M Fatih; Elif Yilmaz Gulec; Gozde Yesil; Jaya Punetha; Zeynep Ocak; Christopher M Grochowski; Ender Karaca; Hatice Mutlu Albayrak; Periyasamy Radhakrishnan; Haktan Bagis Erdem; Ibrahim Sahin; Timur Yildirim; Ilhan A Bayhan; Aysegul Bursali; Muhsin Elmas; Zafer Yuksel; Ozturk Ozdemir; Fatma Silan; Onur Yildiz; Osman Yesilbas; Sedat Isikay; Burhan Balta; Shen Gu; Shalini N Jhangiani; Harsha Doddapaneni; Jianhong Hu; Donna M Muzny; Eric Boerwinkle; Richard A Gibbs; Konstantinos Tsiakas; Maja Hempel; Katta Mohan Girisha; Davut Gul; Jennifer E Posey; Nursel H Elcioglu; Beyhan Tuysuz; James R Lupski Journal: Am J Hum Genet Date: 2019-06-20 Impact factor: 11.025
Authors: Amy Li; Shane R Nelson; Sheema Rahmanseresht; Filip Braet; Anabelle S Cornachione; Samantha Beck Previs; Thomas S O'Leary; James W McNamara; Dilson E Rassier; Sakthivel Sadayappan; Michael J Previs; David M Warshaw Journal: Proc Natl Acad Sci U S A Date: 2019-10-07 Impact factor: 11.205
Authors: Jennifer A Wambach; Georg M Stettner; Tobias B Haack; Karin Writzl; Andreja Škofljanec; Aleš Maver; Francina Munell; Stephan Ossowski; Mattia Bosio; Daniel J Wegner; Marwan Shinawi; Dustin Baldridge; Bader Alhaddad; Tim M Strom; Dorothy K Grange; Ekkehard Wilichowski; Robin Troxell; James Collins; Barbara B Warner; Robert E Schmidt; Alan Pestronk; F Sessions Cole; Robert Steinfeld Journal: Hum Mutat Date: 2017-08-17 Impact factor: 4.878